Navigation Links
Leukemia Gets A New Drug

Researchers from the Flanders Interuniversity Institute for Biotechnology (VIB) affiliated to the Catholic University of Leuven say that Sorafenib (Nexavar) is a better drug than Glivec for Chronic Eosinophilic Leukemia //(CEL). They said that although Glivec has a good track record, it is known to cause resistance after some time and hence the need to use an alternative drug.

This finding is not only important for CEL patients, but it also provides a new approach for treating specific forms of leukemia. It is clear from this research that a combination of targeted drugs provides a greater chance of lifelong effective treatment. Chronic Eosinophilic Leukemia (CEL) Our body's white blood cells combat foreign intruders (such as viruses and bacteria). However, in chronic leukemia, the cells in the bone marrow that should develop into white blood cells multiply uncontrollably. These blood cells do not function properly, jeopardizing the production of normal blood cells. Among other consequences, this makes patients more susceptible to infections. Chronic leukemia appears in several forms − in CEL, a rare form of leukemia, the excessive increase of eosinophils (a certain type of white blood cell) can cause tissue damage in the heart, the skin, and the central nervous system. The mechanism behind the cause Under normal circumstances, our body regulates the production of white blood cells very precisely by means of a targeted activation of tyrosine kinases, which start this production. But sometimes defects in the DNA cause these tyrosine kinases to be active continuously, giving rise to diseases like leukemia. In 2003, Jan Cools and his colleagues under the direction of Peter Marynen, along with colleagues Elizabeth Stover and Gary Gilliland from Boston, discovered that CEL is caused by this kind of defective activation of the tyrosine kinase FIP1L1-PDGFRá. Now, with additional research, they have uncovered the molecular mechanism behind the abn ormal activation of FIP1L1-PDGFRá. This new research is being published this week on the website of the scientific journal PNAS. Resistance to the remedy In the fight against CEL (and other forms of leukemia), scientists use proteins that inhibit the tyrosine kinases. Glivec is such an inhibitor and is effective against CEL because it specifically inhibits the activity of FIP1L1-PDGFRá. However, CEL patients must take Glivec every day for the rest of their lives − and recent research shows that, over time, alterations in the DNA can arise, causing resistance to Glivec. The longer Glivec is taken, the greater the chance resistance will develop. At that point, treatment with Glivec is no longer effective. On the path to a long-lasting effective treatment This problem prompted VIB researchers Els Lierman and Jan Cools to look for alternatives. They have found that Sorafenib, another inhibitor, works effectively in treating the resistant form of CEL. Sorafenib is already on the market in the US as a remedy for kidney tumors. This new research indicates that, to be able to treat certain forms of leukemia (like CEL) effectively over a long period of time, several inhibitors must be used, either together or successively. The scientists emphasize the importance of testing known inhibitors for their effectiveness against CEL and other forms of leukemia. This research has recently appeared in the scientific journal Blood. Contact: Sooike Stoops info@vib.be 329-244-6611 VIB, Flanders Interuniversity Institute of Biotechnology Source: Eurekaler
'"/>




Related medicine news :

1. Cyclosporin A Treats Leukemia Complications
2. Leukemia pill shows promise against stomach cancer
3. Aspirin Lowers Leukemia Risk
4. Hope for Chemo-Resistant Leukemia Patients
5. Genes Found To Help Leukemia Treatment
6. Looking Towards More Effective Leukemia Treatment
7. Diet Found To Offer Protection Against Leukemia
8. Exposure To Night Light may Increase The Risk Of Leukemia
9. Skin Allergies Found To Increase The Risk Of Leukemia
10. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
11. Night Light Found To Increase The Risk Of Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
Breaking Medicine Technology: